Chang Tung-Ti, Huang Chieh-Chen, Hsu Ching-Hsiang
Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan.
Phytother Res. 2006 May;20(5):342-7. doi: 10.1002/ptr.1843.
Although some formulae of traditional Chinese medicines (TCM) have been used for antiasthma treatment, few of them have had sufficient discussion on their efficacy, safety and mechanisms. In this study, the availability of the TCM formula STA-1 for the treatment of allergic asthma was investigated by conducting a double-blind, placebo-controlled and randomized trial. One hundred and twenty patients between the ages of 5 to 20 years with mild-to-moderate asthma were included. These patients were treated with either STA-1 or placebo in a dose of 80 g/kg/day and were administered twice daily for 6 months. The main outcome measures were a daily diary record of symptoms, supplementary bronchodilator and glucocorticoid treatment, changes of pulmonary function (forced expiratory volume in 1 s), changes of total and Dermatophagoides pteronyssinus (DP)-specific IgE and side effects. The results showed a statistically significant reduction of symptom scores, systemic steroid dose, total IgE and specific IgE in the STA-1 group. Furthermore, STA-1 also improved the pulmonary lung function FEV(1) compared with the placebo group and only minimal side effects were shown. These results suggested that STA-1 is available for the treatment of mild-to-moderate chronic asthma.
虽然一些中药配方已用于哮喘治疗，但其中很少有对其疗效、安全性和作用机制进行充分讨论的。在本研究中，通过进行一项双盲、安慰剂对照和随机试验，研究了中药配方STA - 1治疗过敏性哮喘的有效性。纳入了120名年龄在5至20岁之间的轻至中度哮喘患者。这些患者以80 g/kg/天的剂量接受STA - 1或安慰剂治疗，每天给药两次，持续6个月。主要观察指标包括症状的每日日记记录、补充支气管扩张剂和糖皮质激素治疗、肺功能变化（1秒用力呼气量）、总IgE和粉尘螨特异性IgE的变化以及副作用。结果显示，STA - 1组的症状评分、全身类固醇剂量、总IgE和特异性IgE在统计学上有显著降低。此外，与安慰剂组相比，STA - 1还改善了肺功能FEV(1)，且仅显示出极小的副作用。这些结果表明，STA - 1可用于治疗轻至中度慢性哮喘。
